Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393770 | 0.93 | LMNA (0.37) | RAB9AMEN1KMT2ALMNAMAPT | |
| N-Ethylmaleimide SCHEMBL15130052 | 0.84 | ALDH1A1 (0.38) | RAB9AMEN1KMT2ALMNAMAPT | |
| SCHEMBL534775 | 0.84 | TSHR (0.44) | ALDH1A1SRD5A2CA12CA1CA2 | |
| SCHEMBL29395801 | 0.84 | HPGD (0.38) | RAB9AMEN1KMT2ALMNAMAPT | |
| SCHEMBL30824732 | 0.84 | SRD5A2 (0.44) | RAB9AMEN1KMT2ALMNAMAPT | |
| SCHEMBL28438497 | 0.82 | HSD17B3 (0.47) | ALDH1A1CA12CA9MAPK1CDC25B | |
| Benzamide SCHEMBL28196827 | 0.82 | CYP2C19 (0.52) | RAB9AMEN1KMT2ALMNAMAPT | |
| SCHEMBL41940 | 0.82 | BACE1 (0.46) | LMNAMAPTALDH1A1CA12CA9 | |
| Benzene SCHEMBL29048034 | 0.82 | BACE1 (0.46) | LMNAMAPTALDH1A1CA12CA9 | |
| Hydrogen Sulfide SCHEMBL28559443 | 0.80 | HSD17B3 (0.46) | ALDH1A1CA12CA9MAPK1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052005-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2024-02-15 | — | — | US | claimed |
| EP-4263582-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | Anastasis Biotec Limited (GB) | 2023-10-25 | — | — | EP | claimed |
| CN-116068167-A | Separation and detection method of extracellular biomacromolecule | 厦门福流生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2022129926-A1 | IMPROVED CELL-PENETRATING PEPTIDES AND FUSION PROTEINS | ANASTASIS BIOTEC LIMITED (GB) | 2022-06-23 | — | — | WO | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| EP-2333548-B1 | Biological indicator | AMERICAN STERILIZER CO (US) | 2014-07-30 | — | — | EP | claimed |
| EP-2701743-A2 | ANTIBODIES SELECTIVE FOR PATHOLOGICAL TAU DIMERS AND PREFIBRILLAR PATHOLOGICAL TAU OLIGOMERS AND THEIR USES IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES | North Western University (US) | 2014-03-05 | — | — | EP | claimed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| US-8420802-B2 | Polymer support | UNIVERSITY OF CAPE TOWN (ZA) | 2013-04-16 | — | — | US | claimed |
| WO-2012149365-A2 | ANTIBODIES SELECTIVE FOR PATHOLOGICAL TAU DIMERS AND PREFIBRILLAR PATHOLOGICAL TAU OLIGOMERS AND THEIR USES IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES | NORTHWESTERN UNIVERSITY (US) | 2012-11-01 | — | — | WO | claimed |
| WO-2011083360-A1 | A POLYMER SUPPORT | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-14 | — | — | WO | claimed |
| EP-2333548-A1 | Biological indicator | American Sterilizer Company (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | claimed |
| US-20100151563-A1 | Biological indicator | AMERICAN STERILIZER COMPANY (US) | 2010-06-17 | — | — | US | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| US-20080199903-A1 | Biological indicator | STERIS INC. (US) | 2008-08-21 | — | — | US | claimed |
| CN-101189519-A | Biological indicator | STERIS INC (US) | 2008-05-28 | — | — | CN | claimed |
| EP-1886143-A1 | BIOLOGICAL INDICATOR | Steris, Inc. (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2007046865-A1 | BIOLOGICAL INDICATOR | STERIS, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20060269983-A1 | Biological indicator | AMERICAN STERILIZER COMPANY | 2006-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | RAB9A 4107/4885MEN1 1477/4885KMT2A 4808/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | RAB9A 4107/4885MEN1 1477/4885KMT2A 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.